Created at Source Raw Value Validated value
Nov. 26, 2021, 10:30 p.m. oms

1. Age less than 18 and more 70 years <br/ >2. Pregnant and lactating women <br/ >3. Patients not willing to give written informed consent <br/ >4. Seriously ill patients requiring intensive care <br/ >5. Known hypersensitivity to Ivermectin drug 6. Subjects who have participated in another investigational drug or research study within 30 days of screening. <br/ >7. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.

1. Age less than 18 and more 70 years <br/ >2. Pregnant and lactating women <br/ >3. Patients not willing to give written informed consent <br/ >4. Seriously ill patients requiring intensive care <br/ >5. Known hypersensitivity to Ivermectin drug 6. Subjects who have participated in another investigational drug or research study within 30 days of screening. <br/ >7. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.

Nov. 13, 2021, 5:33 p.m. oms

N/A

N/A

July 30, 2021, 1:30 p.m. oms

1. Age less than 18 and more 70 years <br/ >2. Pregnant and lactating women <br/ >3. Patients not willing to give written informed consent <br/ >4. Seriously ill patients requiring intensive care <br/ >5. Known hypersensitivity to Ivermectin drug 6. Subjects who have participated in another investigational drug or research study within 30 days of screening. <br/ >7. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.

1. Age less than 18 and more 70 years <br/ >2. Pregnant and lactating women <br/ >3. Patients not willing to give written informed consent <br/ >4. Seriously ill patients requiring intensive care <br/ >5. Known hypersensitivity to Ivermectin drug 6. Subjects who have participated in another investigational drug or research study within 30 days of screening. <br/ >7. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.